Amifampridine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Amifampridine: voltage-gated potassium channel blocker → glaucoma
One-Sentence Summary
Amifampridine is a potassium channel blocker that is marketed in Canada. The TxGNN model predicts it may be relevant to glaucoma, but the data compiled for this report contain no clinical trials and no publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | glaucoma |
| TxGNN Prediction Score | 0.9971 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Amifampridine blocks voltage-gated potassium channels. This prolongs depolarization at the nerve terminal and increases neurotransmitter release at the neuromuscular junction. Detailed mechanism of action data are not available in the data compiled for this report, so this description reflects the general, known pharmacology of the drug class.
No clear link has been established between this mechanism and the pathophysiology of glaucoma, which involves intraocular pressure and loss of retinal ganglion cells. The high TxGNN score is a computational output only. It is not supported by any trial, publication or mechanistic study in the data compiled here. The prediction should be regarded as a hypothesis that requires independent biological justification before any further investment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02502984 | FIRDAPSE | Not recorded | Not recorded |
| 02503034 | RUZURGI | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: 68 interacting drugs were identified in the interaction database. Of the 20 listed in the data compiled for this report, one is rated Major: bupropion. The rest are rated Moderate, including:
- Corticosteroids: hydrocortisone, betamethasone, dexamethasone, prednisolone, prednisone
- Stimulants and anorectics: ephedrine, phentermine, fenfluramine, dexfenfluramine, diethylpropion, mazindol, sibutramine
- Opioids: morphine (including liposomal) and opium
- Other: levofloxacin, metoclopramide, dronabinol, polyethylene glycol (3350 with electrolytes)
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The glaucoma prediction has a high model score (0.9971) but no supporting trials, literature or established mechanism, so the evidence level is L5. There is no basis to advance it at this stage.
To proceed, the following is needed:
- A plausible mechanistic rationale linking potassium channel blockade to glaucoma pathophysiology
- Preclinical studies that directly address glaucoma
- Detailed mechanism of action data
- Package insert warnings and contraindications from Health Canada, for safety screening
- Assessment of route compatibility, since an ocular indication may require a different formulation or route of administration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.